Filed Pursuant to Rule 424(b)(3)
Registration No. 333-275229
PROSPECTUS SUPPLEMENT
(to Prospectus dated November 7, 2023)
Portage Biotech Inc.
481,581 Ordinary Shares underlying Warrants
This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated November 7, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No. 333-275229), as amended most recently by the post-effective amendment filed on August 23, 2024, with the information contained in our current report on Form 6-K, furnished to the Securities and Exchange Commission on March 27, 2025 (the “March 27, 2025 Form 6-K”). Accordingly, we have attached the March 27, 2025 Form 6-K to this prospectus supplement.
This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.
Our Ordinary Shares are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “PRTG”. On March 27, 2025, the closing sale price of our Ordinary Shares as reported on Nasdaq was $4.73.
Investing in the securities offered in the Prospectus involves a high degree of risk. Before making any investment in these securities, you should consider carefully the risks and uncertainties in the section entitled “Risk Factors” beginning on page 9 of the Prospectus, and in the other documents that are incorporated by reference into the Prospectus.
Neither the Securities and Exchange Commission nor any state or non-U.S. regulatory body has approved or disapproved of the securities offered in the Prospectus or passed upon the accuracy or adequacy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is March 27, 2025
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2025
Commission File Number: 001-40086
PORTAGE BIOTECH INC.
(Translation of registrant's name into English)
Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
INCORPORATION BY REFERENCE
This report on Form 6-K (including any exhibits attached hereto) shall be deemed to be incorporated by reference into the registration statement on Form S-8 (File No. 333-275842) of Portage Biotech Inc. (including any prospectuses forming a part of such registration statement) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
On March 27, 2025, Portage Biotech Inc. (the “Company”) issued a press release announcing promising preclinical results in mesothelioma supporting first-in-human trial of PORT-7. A copy of the press release is filed herewith as Exhibit 99.1.
Exhibits | |
Exhibit Number | Description |
99.1 | Press Release dated March 27, 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Portage Biotech Inc. | |
(Registrant) | |
Date: March 27, 2025 | /s/ Alexander Pickett |
Alexander Pickett | |
Chief Executive Officer | |
EXHIBIT 99.1
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibody
DOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma e Oncologia Ambientale, at the 2025 European Lung Cancer Congress (ELCC), held in Paris, France March 26-29. The new data demonstrate both single agent activity for PORT-7, and a dramatic >90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma. Immunohistochemistry of the tumors revealed a significant infiltration of both CD3 and CD45 positive immune effector cells. Mesothelioma is an aggressive cancer with limited treatment options in need of novel approaches to overcome immune resistance. To our knowledge, this is the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor. Portage is making preparations to commence a first-in-human clinical trial with PORT-7.
Combining PORT-6 and PORT-7 for a More Comprehensive Immunotherapy Approach
In parallel, Portage is advancing the dose escalation of PORT-6, a potent and selective inhibitor of the A2A adenosine receptor. Portage’s plan is to ultimately co-administer PORT-6 with PORT-7 in the ongoing ADPORT-601 trial. This will mark the first time two highly selective A2A and A2B antagonists are combined in patients, with the aim of achieving a complete blockade of adenosine-induced immunosuppression in the tumor microenvironment. This innovative approach is designed to fully neutralize adenosine-mediated immune suppression, enhance anti-tumor responses, and broaden the impact of immunotherapy in solid tumors.
About Portage Biotech
Portage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of
novel biologics to transform the immune system’s ability to fight cancer. For more information, visit www.portagebiotech.com.
Forward-Looking Statements
All statements in this news release, other than statements of historical
facts, including without limitation, statements regarding the Company’s business strategy, plans and objectives of management for
future operations and those statements preceded by, followed by or that otherwise include the words “believe,” “expects,”
“anticipates,” “intends,” “estimates,” “will,” “may,” “plans,”
“potential,” “continues,” or similar expressions or variations on such expressions are forward-looking statements.
As a result, forward-looking statements are subject to certain risks and uncertainties, including, but not limited to: the risk that the
Company may not secure financing, the uncertainty of the Company’s ability to continue as a going concern, scientific results may
not be as expected, and other factors set forth in “Item 3 - Key Information-Risk Factors” in the Company’s Annual Report
on Form 20-F for the year ended March 31, 2024 and “Business Environment – Risk Factors” in the Company’s Management’s
Discussion and Analysis for the Three and Six Months ended September 30, 2024, filed as Exhibit 99.2 to the Company’s Form 6-K.
Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should
not be placed on them as actual results may differ materially from these forward-looking statements. The forward-looking statements contained
in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking
statements or information, except as required by law.
For More Information:
Portage Biotech
Alexander Pickett,
Chief Executive Officer
[email protected]